logo

For the Inventor, By the Inventor

Hampton, NJ, United States of America

Celldex Therapeutics Limited


USPTO Granted Patents = 45

% Expired Patents = 44.4



Trademarks = 2

Forward Citations = 148

Loading Chart...
Loading Chart...

79 inventors (with patents filed for the assignee):

goldMedal Tibor P Keler (22 out of 40 patents)

silverMedal Lizhen He (15 out of 15 patents)

bronzeMedal Laura A Vitale (13 out of 15 patents)

4.  Yaron R Hadari (8 out of 24 patents)

5.  Lawrence J Thomas (8 out of 12 patents)

6.  Joel Goldstein (7 out of 13 patents)

7.  Henry C Marsh (6 out of 17 patents)

8.  Venky Ramakrishna (6 out of 8 patents)

9.  Elizabeth M Mandel-Bausch (6 out of 7 patents)

10.  Francis Joseph Carr (5 out of 44 patents)

11.  Timothy David Jones (5 out of 35 patents)

12.  Tom O'Neill (4 out of 4 patents)

13.  Andrea Crocker (4 out of 4 patents)

14.  Karuna Sundarapandiyan (4 out of 5 patents)

15.  Jenifer Widger (4 out of 4 patents)


Core Competencies:
Agonistic Antibodies
Anti-PD-1 Antibody
Chimeric Antigen Receptors
Bispecific Constructs
Anti-KIT Antibodies
Immune Response Enhancement
Polynucleotides Encoding Antibodies
Monoclonal Antibodies
Antibody Vaccine Conjugates
Dendritic Cells
Cancer Treatment
Eye Diseases Treatment

45 patents:

1. 12297266 - Agonistic antibodies that bind human CD40 and uses thereof (2025-05-13),
2. 11987626 - Treatment of eosinophil or mast cell related disorders (2024-05-21),
3. 11965031 - Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment (2024-04-23),
4. 11891452 - Anti-kit antibodies and uses thereof (2024-02-06),
5. 11884734 - Anti-MET antibodies and methods of use thereof (2024-01-30),
6. 11884699 - Anti-KIT antibodies and uses thereof (2024-01-30),
7. 11541076 - Chimeric antigen receptors targeting TIM-1 (2023-01-03),
8. 11459393 - Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs (2022-10-04),
9. 11332537 - Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs (2022-05-17),
10. 11180566 - Antibodies that bind human CD27 and uses thereof (2021-11-23),
11. 11091559 - Anti-ALK antibodies and methods for use thereof (2021-08-17),
12. 10941201 - Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies (2021-03-09),
13. 10865244 - Nucleic acids encoding agonistic antibodies that bind CD40 (2020-12-15),
14. 10793639 - Methods of treating by administering anti-kit antibodies (2020-10-06),
15. 10781267 - Methods of treating by administering anti-kit antibodies (2020-09-22),
Celldex Therapeutics Limited is a biotechnology company focused on the development and commercialization of immunotherapy and antibody-based therapeutics for the treatment of cancer. Their novel approach harnesses the power of the immune system to target and eliminate cancer cells. With a strong pipeline of innovative products and a commitment to improving patient outcomes, Celldex Therapeutics Limited is dedicated to advancing the field of oncology and finding effective treatments for patients in need.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Celldex Therapeutics Limited
45 Patents

#2 in Hampton, NJ

#323 in New Jersey

#7,763 in US

#15,403 in the World

Hampton, NJ (US)
Hampton, NJ, United States of America

Celldex Therapeutics Limited

Forward Citations = 148

79 inventors:

goldMedal Tibor P Keler (22 out of 40 patents)

silverMedal Lizhen He (15 out of 15 patents)

bronzeMedal Laura A Vitale (13 out of 15 patents)

4.  Yaron R Hadari (8 out of 24 patents)

5.  Lawrence J Thomas (8 out of 12 patents)

Please report any incorrect information to [email protected]
Loading…